164 related articles for article (PubMed ID: 2468602)
1. Immunotherapy with lymphokine combinations.
Mulé JJ; Rosenberg SA
Important Adv Oncol; 1989; ():99-126. PubMed ID: 2468602
[No Abstract] [Full Text] [Related]
2. [Immunotherapy of malignant diseases].
Dorval T; Michon J; Tartour E; Fridman WH
Bull Cancer; 1995; 82 Suppl 2():127s-138s. PubMed ID: 7542946
[TBL] [Abstract][Full Text] [Related]
3. Symposium on diagnosis and treatment of cancer. Recent progress.
Jpn J Med; 1988 Feb; 27(1):96-112. PubMed ID: 2452911
[No Abstract] [Full Text] [Related]
4. Intracavitary administration of biological agents.
Markman M
J Biol Response Mod; 1987 Aug; 6(4):404-11. PubMed ID: 2442312
[TBL] [Abstract][Full Text] [Related]
5. Immunological approaches to the treatment of malignant disease.
Guillou PJ
J R Coll Surg Edinb; 1988 Feb; 33(1):2-8. PubMed ID: 2458468
[No Abstract] [Full Text] [Related]
6. Tumor necrosis therapy antibody interleukin-2 fusion protein elicits prolonged and targeted antitumor effects in vivo.
Ye L; Fan J; Shi X; Tao Q; Ye D; Xian Z; Zeng X; Li Y; Feng M; Ju D
Appl Microbiol Biotechnol; 2014 May; 98(9):4053-61. PubMed ID: 24276620
[TBL] [Abstract][Full Text] [Related]
7. [Immunotherapy of metastatic renal cell cancer].
Manseck A; Wirth M
Urologe A; 1993 Sep; 32(5):360-73. PubMed ID: 7692655
[TBL] [Abstract][Full Text] [Related]
8. Biological response modifiers: the new immunotherapy.
Foon KA
Cancer Res; 1989 Apr; 49(7):1621-39. PubMed ID: 2466558
[No Abstract] [Full Text] [Related]
9. Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study.
Eisenbeis CF; Grainger A; Fischer B; Baiocchi RA; Carrodeguas L; Roychowdhury S; Chen L; Banks AL; Davis T; Young D; Kelbick N; Stephens J; Byrd JC; Grever MR; Caligiuri MA; Porcu P
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6101-10. PubMed ID: 15447996
[TBL] [Abstract][Full Text] [Related]
10. [Prospects for improving antibody therapy for carcinoma].
Liu XY
Zhonghua Yi Xue Za Zhi; 2004 Jul; 84(14):1145-6. PubMed ID: 15387972
[No Abstract] [Full Text] [Related]
11. Antibody-interleukin 2 fusion proteins: a new approach to cancer therapy.
Reisfeld RA; Gillies SD
J Clin Lab Anal; 1996; 10(3):160-6. PubMed ID: 8731505
[No Abstract] [Full Text] [Related]
12. Biologic therapy of melanoma with cytokines and lymphocytes.
Bear HD; Hamad GG; Kostuchenko PJ
Semin Surg Oncol; 1996; 12(6):436-45. PubMed ID: 8914208
[TBL] [Abstract][Full Text] [Related]
13. Serotherapy of cancer.
Harris DT; Mastrangelo MJ
Semin Oncol; 1989 Jun; 16(3):180-98. PubMed ID: 2658082
[No Abstract] [Full Text] [Related]
14. Cytokines.
Holmlund JT
Cancer Chemother Biol Response Modif; 1993; 14():150-206. PubMed ID: 7508728
[No Abstract] [Full Text] [Related]
15. [Carcinogenesis and immunobiology of tumors. Scientific and clinical aspects].
Granov AM; Molchanov OE
Vopr Onkol; 2008; 54(4):401-9. PubMed ID: 18942393
[No Abstract] [Full Text] [Related]
16. Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans.
Rubin JT; Elwood LJ; Rosenberg SA; Lotze MT
Cancer Res; 1989 Dec; 49(24 Pt 1):7086-92. PubMed ID: 2582450
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for metastatic renal cell carcinoma.
McDermott DF; Rini BI
BJU Int; 2007 May; 99(5 Pt B):1282-8. PubMed ID: 17441925
[No Abstract] [Full Text] [Related]
18. Immunotherapy for infection and malignancy in children with cancer.
Frost JD; Sondel PM
Adv Pediatr; 1994; 41():385-413. PubMed ID: 7992692
[No Abstract] [Full Text] [Related]
19. Cancer immunotherapy.
Schuster M; Nechansky A; Kircheis R
Biotechnol J; 2006 Feb; 1(2):138-47. PubMed ID: 16892244
[TBL] [Abstract][Full Text] [Related]
20. Does chemotherapy augment anti-tumor immunotherapy by preferential impairment of regulatory T cells?
Zhang L; Dermawan KT; Jin ML; Xiong SD; Chu YW
Med Hypotheses; 2008 Nov; 71(5):802-4. PubMed ID: 18691831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
